Screener / SEC EDGAR /CIK 0000730272 /10-K filed Feb 26, 2026, compared with Mar 14, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Repligen Corp RGEN

Compare with peers Embed

RGEN among the 162 companies we cover

Where it stands · the better end on the right. The band holds the middle half; the line is the median.

All 162
Sales growth
+4.8%+20.2%
+16.4%51st of 155 · median +10.5%
Net margin
-4.1%15.3%
-1.5%112th of 154 · median 6.8%
Return on equity
-5.2%18.5%
-0.6%103rd of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
13.2%60th of 145 · median 10.0%
Debt / equity (less is better)
1.160.42
0.2721st of 108 · median 0.69

RGEN and 9 peers, year by year

The 9 Health care companies closest to RGEN in revenue over the last twelve months. Every number is from the 10-K and links to it in SEC's Inline XBRL viewer.

Choose the peers

Health care companies (up to 9):

Each company's latest fiscal year
CompanyYearRevenueSales growthGross marginOperating marginNet marginFCF marginReturn on equityDebt / equity
RGEN Repligen Corp FY2025 $738.3M+16.4%-7.5%6.6%12.7%2.3%0.26
IRTC iRhythm Holdings, Inc. FY2025 $747.1M+26.2%70.6%−7.7%−6.0%4.6%−29.2%-
SUPN Supernus, Inc. FY2025 $719.0M+8.6%-−8.7%−5.4%6.4%−3.6%-
AXSM Axsome Therapeutics, Inc. FY2025 $638.5M+65.5%-−26.1%−28.7%−14.7%n/m2.13
INSP Inspire Medical Systems, Inc. FY2025 $912.0M+13.6%85.4%5.6%15.9%8.6%18.6%-
RARE Ultragenyx Pharmaceutical Inc. FY2025 $673.0M+20.2%-−79.5%−85.4%−70.1%n/m-
TMDX TransMedics Group, Inc. FY2025 $605.5M+37.1%59.9%17.9%31.4%22.1%40.2%-
TGTX TG Therapeutics, Inc. FY2025 $616.3M+87.3%-20.0%72.6%−4.1%69.0%0.38
GKOS GLAUKOS Corp FY2025 $507.4M+32.3%55.7%−39.3%−37.0%−4.4%−28.6%-
TARS Tarsus Pharmaceuticals, Inc. FY2025 $451.4M+147%-−15.7%−14.7%−4.9%−19.3%0.21

Each company, year by year

Bars: revenue, each company on its own scale. Line: net margin, on one scale for all. FY2016 to FY2025 · 10-K XBRL

RGENRepligen Corp
FY2016 revenue $104.5MFY2017 revenue $141.2MFY2018 revenue $194.0MFY2019 revenue $270.2MFY2020 revenue $366.3MFY2021 revenue $670.5MFY2022 revenue $801.5MFY2023 revenue $632.4MFY2024 revenue $634.4MFY2025 revenue $738.3M FY2016 net margin 11.2%FY2017 net margin 20.1%FY2018 net margin 8.6%FY2019 net margin 7.9%FY2020 net margin 16.4%FY2021 net margin 19.1%FY2022 net margin 23.2%FY2023 net margin 5.6%FY2024 net margin −4.0%FY2025 net margin 6.6% FY2016FY2025
Revenue$738.3M Growth+16.4% Net margin6.6%
IRTCiRhythm Holdings, Inc.
FY2016 revenue $64.1MFY2017 revenue $99.1MFY2018 revenue $147.3MFY2019 revenue $214.6MFY2020 revenue $265.2MFY2021 revenue $322.8MFY2022 revenue $410.9MFY2023 revenue $492.7MFY2024 revenue $591.8MFY2025 revenue $747.1M FY2016 net margin −32.6%FY2017 net margin −30.0%FY2018 net margin −34.2%FY2019 net margin −25.4%FY2020 net margin −16.5%FY2021 net margin −31.4%FY2022 net margin −28.3%FY2023 net margin −25.0%FY2024 net margin −19.1%FY2025 net margin −6.0% FY2016FY2025
Revenue$747.1M Growth+26.2% Net margin−6.0%
SUPNSupernus, Inc.
FY2016 revenue $215.0MFY2017 revenue $302.2MFY2018 revenue $408.9MFY2019 revenue $392.8MFY2020 revenue $520.4MFY2021 revenue $579.8MFY2022 revenue $667.2MFY2023 revenue $607.5MFY2024 revenue $661.8MFY2025 revenue $719.0M FY2016 net margin 42.4%FY2017 net margin 19.0%FY2018 net margin 27.1%FY2019 net margin 28.8%FY2020 net margin 24.4%FY2021 net margin 9.2%FY2022 net margin 9.1%FY2023 net margin 0.2%FY2024 net margin 11.2%FY2025 net margin −5.4% FY2016FY2025
Revenue$719.0M Growth+8.6% Net margin−5.4%
AXSMAxsome Therapeutics, Inc.
FY2022 revenue $50.0MFY2023 revenue $270.6MFY2024 revenue $385.7MFY2025 revenue $638.5M FY2022 net margin −374.0%FY2023 net margin −88.4%FY2024 net margin −74.5%FY2025 net margin −28.7% FY2016FY2025
Revenue$638.5M Growth+65.5% Net margin−28.7%
INSPInspire Medical Systems, Inc.
FY2016 revenue $16.4MFY2017 revenue $28.6MFY2018 revenue $50.6MFY2019 revenue $82.0MFY2020 revenue $115.4MFY2021 revenue $233.4MFY2022 revenue $407.9MFY2023 revenue $624.8MFY2024 revenue $802.8MFY2025 revenue $912.0M FY2016 net margin −112.8%FY2017 net margin −61.3%FY2018 net margin −43.1%FY2019 net margin −40.5%FY2020 net margin −49.6%FY2021 net margin −18.0%FY2022 net margin −11.0%FY2023 net margin −3.4%FY2024 net margin 6.7%FY2025 net margin 15.9% FY2016FY2025
Revenue$912.0M Growth+13.6% Net margin15.9%
RAREUltragenyx Pharmaceutical Inc.
FY2016 revenue $133KFY2017 revenue $2.6MFY2018 revenue $51.5MFY2019 revenue $103.7MFY2020 revenue $271.0MFY2021 revenue $351.4MFY2022 revenue $363.3MFY2023 revenue $434.0MFY2024 revenue $560.0MFY2025 revenue $673.0M FY2018 net margin −383.7%FY2019 net margin −388.3%FY2020 net margin −68.8%FY2021 net margin −129.2%FY2022 net margin −194.7%FY2023 net margin −139.9%FY2024 net margin −101.6%FY2025 net margin −85.4% FY2016FY2025
Revenue$673.0M Growth+20.2% Net margin−85.4%
TMDXTransMedics Group, Inc.
FY2018 revenue $14.7MFY2019 revenue $25.8MFY2020 revenue $28.4MFY2021 revenue $31.4MFY2022 revenue $93.5MFY2023 revenue $241.6MFY2024 revenue $441.5MFY2025 revenue $605.5M FY2018 net margin −162.1%FY2019 net margin −129.8%FY2020 net margin −101.4%FY2021 net margin −140.9%FY2022 net margin −38.8%FY2023 net margin −10.4%FY2024 net margin 8.0%FY2025 net margin 31.4% FY2016FY2025
Revenue$605.5M Growth+37.1% Net margin31.4%
TGTXTG Therapeutics, Inc.
FY2016 revenue $152KFY2017 revenue $152KFY2018 revenue $152KFY2019 revenue $152KFY2020 revenue $152KFY2021 revenue $6.7MFY2022 revenue $2.8MFY2023 revenue $233.7MFY2024 revenue $329.0MFY2025 revenue $616.3M FY2023 net margin 5.4%FY2024 net margin 7.1%FY2025 net margin 72.6% FY2016FY2025
Revenue$616.3M Growth+87.3% Net margin72.6%
GKOSGLAUKOS Corp
FY2016 revenue $114.4MFY2017 revenue $159.3MFY2018 revenue $181.3MFY2019 revenue $237.0MFY2020 revenue $225.0MFY2021 revenue $294.0MFY2022 revenue $282.9MFY2023 revenue $314.7MFY2024 revenue $383.5MFY2025 revenue $507.4M FY2016 net margin 4.0%FY2017 net margin −0.1%FY2018 net margin −7.1%FY2019 net margin 6.5%FY2020 net margin −53.5%FY2021 net margin −16.9%FY2022 net margin −35.1%FY2023 net margin −42.8%FY2024 net margin −38.2%FY2025 net margin −37.0% FY2016FY2025
Revenue$507.4M Growth+32.3% Net margin−37.0%
TARSTarsus Pharmaceuticals, Inc.
FY2021 revenue $57.0MFY2022 revenue $25.8MFY2023 revenue $17.4MFY2024 revenue $183.0MFY2025 revenue $451.4M FY2021 net margin −24.2%FY2022 net margin −240.5%FY2023 net margin −778.9%FY2024 net margin −63.2%FY2025 net margin −14.7% FY2016FY2025
Revenue$451.4M Growth+147% Net margin−14.7%

Who rewrote the most

Share of the words changed in Risk Factors and in MD&A, latest 10-K against the one before

Risk FactorsMD&AEach company's latest 10-K, so the dates differ. A company that rewrote much may have reorganized the text.

Revenue, FY2016 to FY2025

Revenue as reported in the 10-K.

$0 $912.0M FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 IRTC: $64.1M, $99.1M, $147.3M, $214.6M, $265.2M, $322.8M, $410.9M, $492.7M, $591.8M, $747.1M IRTC SUPN: $215.0M, $302.2M, $408.9M, $392.8M, $520.4M, $579.8M, $667.2M, $607.5M, $661.8M, $719.0M SUPN AXSM: -, -, -, -, $0, $0, $50.0M, $270.6M, $385.7M, $638.5M AXSM INSP: $16.4M, $28.6M, $50.6M, $82.0M, $115.4M, $233.4M, $407.9M, $624.8M, $802.8M, $912.0M INSP RARE: $133K, $2.6M, $51.5M, $103.7M, $271.0M, $351.4M, $363.3M, $434.0M, $560.0M, $673.0M RARE TMDX: -, -, $14.7M, $25.8M, $28.4M, $31.4M, $93.5M, $241.6M, $441.5M, $605.5M TMDX TGTX: $152K, $152K, $152K, $152K, $152K, $6.7M, $2.8M, $233.7M, $329.0M, $616.3M TGTX GKOS: $114.4M, $159.3M, $181.3M, $237.0M, $225.0M, $294.0M, $282.9M, $314.7M, $383.5M, $507.4M GKOS TARS: -, -, -, -, $0, $57.0M, $25.8M, $17.4M, $183.0M, $451.4M TARS RGEN: $104.5M, $141.2M, $194.0M, $270.2M, $366.3M, $670.5M, $801.5M, $632.4M, $634.4M, $738.3M RGEN
RGEN is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from $0 to $912.0M. A gap is a year with no number. A ring marks where a line starts: AXSM, TMDX, TARS have no earlier 10-K here.

Sales growth, FY2016 to FY2025

Revenue against the fiscal year before.

−58.4% +949% FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 IRTC: +77.3%, +53.7%, +48.6%, +45.7%, +23.6%, +21.7%, +27.3%, +19.9%, +20.1%, +26.2% IRTC SUPN: +45.8%, +40.6%, +35.3%, −3.9%, +32.5%, +11.4%, +15.1%, −8.9%, +8.9%, +8.6% SUPN AXSM: -, -, -, -, -, -, -, +441%, +42.5%, +65.5% AXSM INSP: -, +73.9%, +77.1%, +62.2%, +40.6%, +102%, +74.7%, +53.2%, +28.5%, +13.6% INSP RARE: -, n/m, n/m, +101%, +161%, +29.7%, +3.4%, +19.5%, +29.0%, +20.2% RARE TMDX: -, -, -, +76.3%, +9.7%, +18.0%, +209%, +159%, +82.7%, +37.1% TMDX TGTX: -, 0.0%, 0.0%, 0.0%, 0.0%, n/m, −58.4%, n/m, +40.8%, +87.3% TGTX GKOS: +59.5%, +39.2%, +13.8%, +30.7%, −5.1%, +30.7%, −3.8%, +11.3%, +21.9%, +32.3% GKOS TARS: -, -, -, -, -, -, −54.7%, −32.4%, +949%, +147% TARS RGEN: +25.1%, +35.1%, +37.4%, +39.3%, +35.5%, +83.1%, +19.5%, −21.1%, +0.3%, +16.4% RGEN
RGEN is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −58.4% to +949%. A gap is a year with no number. A ring marks where a line starts: AXSM, INSP, RARE, TMDX, TGTX, TARS have no earlier 10-K here.

Gross margin, FY2016 to FY2025

Gross profit / revenue.

39.1% 86.8% FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 IRTC: 67.4%, 71.5%, 73.7%, 75.5%, 73.5%, 66.2%, 68.5%, 67.3%, 68.9%, 70.6% IRTC INSP: 76.2%, 78.9%, 80.1%, 83.4%, 84.7%, 85.7%, 83.8%, 84.5%, 84.7%, 85.4% INSP TMDX: -, -, 39.1%, 53.6%, 58.7%, 67.4%, 69.8%, 63.8%, 59.4%, 59.9% TMDX GKOS: 85.9%, 86.8%, 86.2%, 83.7%, 59.2%, 77.3%, 75.6%, 76.0%, 75.5%, 55.7% GKOS
RGEN is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from 39.1% to 86.8%. A gap is a year with no number. A ring marks where a line starts: TMDX has no earlier 10-K here.
CompanyFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
RGEN Dec ----------
IRTC Dec 67.4%71.5%73.7%75.5%73.5%66.2%68.5%67.3%68.9%70.6%
SUPN Dec ----------
AXSM Dec ----------
INSP Dec 76.2%78.9%80.1%83.4%84.7%85.7%83.8%84.5%84.7%85.4%
RARE Dec ----------
TMDX Dec --39.1%53.6%58.7%67.4%69.8%63.8%59.4%59.9%
TGTX Dec ----------
GKOS Dec 85.9%86.8%86.2%83.7%59.2%77.3%75.6%76.0%75.5%55.7%
TARS Dec ----------
Peer median76.2%78.9%76.9%79.5%66.4%72.4%72.7%71.7%72.2%65.2%

Operating margin, FY2016 to FY2025

Operating income / revenue.

−820.5% 37.8% FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 IRTC: −24.3%, −27.8%, −31.0%, −25.5%, −16.5%, −31.0%, −27.7%, −25.4%, −19.5%, −7.7% IRTC SUPN: 25.2%, 32.9%, 35.3%, 37.8%, 33.4%, 14.8%, 6.9%, −0.9%, 12.3%, −8.7% SUPN AXSM: -, -, -, -, -, -, −359.3%, −85.7%, −72.7%, −26.1% AXSM INSP: −105.0%, −56.0%, −40.3%, −42.5%, −48.7%, −17.1%, −11.7%, −6.4%, 4.5%, 5.6% INSP RARE: n/m, n/m, −721.2%, −409.0%, −121.8%, −108.6%, −178.6%, −131.1%, −95.7%, −79.5% RARE TMDX: -, -, −138.1%, −114.5%, −93.0%, −125.6%, −33.6%, −11.9%, 8.5%, 17.9% TMDX TGTX: n/m, n/m, n/m, n/m, n/m, n/m, n/m, 8.8%, 12.7%, 20.0% TGTX GKOS: 3.7%, −1.4%, −7.2%, −21.2%, −54.9%, −11.2%, −29.1%, −40.9%, −31.9%, −39.3% GKOS TARS: -, -, -, -, -, −21.3%, −242.9%, −820.5%, −65.9%, −15.7% TARS RGEN: 15.3%, 9.9%, 13.4%, 13.4%, 19.1%, 24.9%, 28.0%, 7.5%, −5.5%, 7.5% RGEN
RGEN is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −820.5% to 37.8%. A gap is a year with no number. A ring marks where a line starts: AXSM, RARE, TMDX, TGTX, TARS have no earlier 10-K here.

Net margin, FY2016 to FY2025

Net income / revenue.

−778.9% 72.6% FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 IRTC: −32.6%, −30.0%, −34.2%, −25.4%, −16.5%, −31.4%, −28.3%, −25.0%, −19.1%, −6.0% IRTC SUPN: 42.4%, 19.0%, 27.1%, 28.8%, 24.4%, 9.2%, 9.1%, 0.2%, 11.2%, −5.4% SUPN AXSM: -, -, -, -, -, -, −374.0%, −88.4%, −74.5%, −28.7% AXSM INSP: −112.8%, −61.3%, −43.1%, −40.5%, −49.6%, −18.0%, −11.0%, −3.4%, 6.7%, 15.9% INSP RARE: n/m, n/m, −383.7%, −388.3%, −68.8%, −129.2%, −194.7%, −139.9%, −101.6%, −85.4% RARE TMDX: -, -, −162.1%, −129.8%, −101.4%, −140.9%, −38.8%, −10.4%, 8.0%, 31.4% TMDX TGTX: n/m, n/m, n/m, n/m, n/m, n/m, n/m, 5.4%, 7.1%, 72.6% TGTX GKOS: 4.0%, −0.1%, −7.1%, 6.5%, −53.5%, −16.9%, −35.1%, −42.8%, −38.2%, −37.0% GKOS TARS: -, -, -, -, -, −24.2%, −240.5%, −778.9%, −63.2%, −14.7% TARS RGEN: 11.2%, 20.1%, 8.6%, 7.9%, 16.4%, 19.1%, 23.2%, 5.6%, −4.0%, 6.6% RGEN
RGEN is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −778.9% to 72.6%. A gap is a year with no number. A ring marks where a line starts: AXSM, RARE, TMDX, TGTX, TARS have no earlier 10-K here.

Free cash flow, FY2016 to FY2025

Cash from operations minus capital spending.

−$519.0M $171.2M FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 IRTC: −$19.4M, −$18.5M, −$34.3M, −$42.3M, −$27.3M, −$65.8M, −$52.8M, −$90.5M, −$30.6M, $34.5M IRTC SUPN: $65.2M, $112.6M, $128.1M, $140.4M, $134.9M, -, $116.4M, $110.5M, $171.2M, $46.0M SUPN AXSM: −$21.4M, −$26.5M, −$30.1M, −$46.4M, −$78.5M, −$108.5M, −$117.2M, −$145.7M, −$128.7M, −$93.9M AXSM INSP: −$18.3M, −$16.2M, −$18.9M, −$35.6M, −$55.5M, −$24.8M, $2.5M, $1.0M, $91.1M, $78.5M INSP RARE: −$171.2M, −$256.6M, −$294.6M, −$370.2M, −$176.1M, −$411.8M, −$496.6M, −$519.0M, −$421.0M, −$472.0M RARE TMDX: -, -, −$26.4M, −$32.5M, −$30.7M, −$32.4M, −$57.7M, −$164.9M, −$80.9M, $133.6M TMDX TGTX: −$61.9M, −$93.8M, −$129.0M, −$132.9M, −$214.9M, −$296.0M, −$176.2M, −$31.4M, −$40.6M, −$25.0M TGTX GKOS: $6.0M, $19.8M, $8.5M, −$5.1M, −$29.9M, −$23.1M, −$63.3M, −$78.0M, −$67.6M, −$22.5M GKOS TARS: -, -, -, −$3.8M, −$21.6M, $3.2M, −$49.5M, −$119.0M, −$84.6M, −$22.3M TARS RGEN: $3.2M, $12.0M, $22.1M, $48.7M, $40.2M, $51.9M, $87.2M, $77.7M, $149.7M, $93.9M RGEN
RGEN is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −$519.0M to $171.2M. A gap is a year with no number. A ring marks where a line starts: TMDX, TARS have no earlier 10-K here.

FCF margin, FY2016 to FY2025

Free cash flow / revenue.

−682.0% 37.3% FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 IRTC: −30.3%, −18.6%, −23.3%, −19.7%, −10.3%, −20.4%, −12.9%, −18.4%, −5.2%, 4.6% IRTC SUPN: 30.3%, 37.3%, 31.3%, 35.7%, 25.9%, -, 17.4%, 18.2%, 25.9%, 6.4% SUPN AXSM: -, -, -, -, -, -, −234.3%, −53.8%, −33.4%, −14.7% AXSM INSP: −111.1%, −56.7%, −37.4%, −43.4%, −48.1%, −10.6%, 0.6%, 0.2%, 11.4%, 8.6% INSP RARE: n/m, n/m, −572.2%, −357.0%, −65.0%, −117.2%, −136.7%, −119.6%, −75.2%, −70.1% RARE TMDX: -, -, −180.1%, −125.6%, −108.3%, −103.2%, −61.8%, −68.2%, −18.3%, 22.1% TMDX TGTX: n/m, n/m, n/m, n/m, n/m, n/m, n/m, −13.4%, −12.3%, −4.1% TGTX GKOS: 5.3%, 12.4%, 4.7%, −2.1%, −13.3%, −7.8%, −22.4%, −24.8%, −17.6%, −4.4% GKOS TARS: -, -, -, -, -, 5.5%, −191.9%, −682.0%, −46.2%, −4.9% TARS RGEN: 3.1%, 8.5%, 11.4%, 18.0%, 11.0%, 7.7%, 10.9%, 12.3%, 23.6%, 12.7% RGEN
RGEN is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −682.0% to 37.3%. A gap is a year with no number. A ring marks where a line starts: AXSM, RARE, TMDX, TGTX, TARS have no earlier 10-K here.

Return on equity, FY2016 to FY2025

Net income / shareholders' equity at the year end.

−176.8% 69.0% FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 IRTC: −22.5%, −37.5%, −96.6%, −40.3%, −12.8%, −36.3%, −48.4%, −58.7%, −124.6%, −29.2% IRTC SUPN: 47.6%, 21.4%, 24.5%, 19.0%, 17.0%, 6.5%, 6.9%, 0.1%, 7.1%, −3.6% SUPN AXSM: −126.1%, −173.1%, n/m, −38.2%, −90.4%, n/m, −170.8%, −125.3%, n/m, n/m AXSM INSP: n/m, n/m, −13.3%, −23.8%, −24.9%, −18.4%, −9.0%, −3.7%, 7.8%, 18.6% INSP RARE: −51.9%, −78.8%, −32.5%, −61.6%, −16.2%, −49.2%, n/m, n/m, n/m, n/m RARE TMDX: -, -, n/m, −61.4%, −27.7%, −65.2%, −19.3%, −18.2%, 15.5%, 40.2% TMDX TGTX: n/m, −176.8%, n/m, n/m, −53.8%, −146.8%, n/m, 7.9%, 10.5%, 69.0% TGTX GKOS: 3.9%, −0.1%, −7.4%, 2.3%, −18.0%, −8.4%, −18.7%, −29.2%, −19.1%, −28.6% GKOS TARS: -, -, n/m, n/m, −16.2%, −8.3%, −32.2%, −69.0%, −51.5%, −19.3% TARS RGEN: 6.9%, 4.8%, 2.7%, 2.0%, 3.9%, 7.3%, 9.7%, 1.8%, −1.3%, 2.3% RGEN
RGEN is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −176.8% to 69.0%. A gap is a year with no number. A ring marks where a line starts: INSP, TMDX, TGTX, TARS have no earlier 10-K here.

Debt / equity, FY2016 to FY2025

Total debt / shareholders' equity at the year end.

0.00 12.40 FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 IRTC: 0.50, 0.56, 0.67, 0.26, 0.10, 0.08, 0.15, 0.17, -, - IRTC SUPN: -, -, -, -, -, 0.46, -, -, -, - SUPN AXSM: 0.45, 0.59, 7.37, 0.11, 0.42, 3.14, 0.86, 0.93, 3.17, 2.13 AXSM INSP: -, 12.40, 0.15, 0.18, 0.11, 0.11, 0.00, -, -, - INSP TMDX: -, -, n/m, 0.62, 0.33, 0.52, 0.31, -, -, - TMDX TGTX: 0.00, 0.00, 0.00, 0.75, 0.06, 0.29, 1.21, 0.63, 1.10, 0.38 TGTX TARS: -, -, -, -, -, 0.00, 0.10, 0.15, 0.32, 0.21 TARS RGEN: -, -, -, -, -, -, -, -, 0.27, 0.26 RGEN
RGEN is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from 0.00 to 12.40. A gap is a year with no number. A ring marks where a line starts: RGEN, SUPN, INSP, TMDX, TARS have no earlier 10-K here.
CompanyFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
RGEN Dec --------0.270.26
IRTC Dec 0.500.560.670.260.100.080.150.17--
SUPN Dec -----0.46----
AXSM Dec 0.450.597.370.110.423.140.860.933.172.13
INSP Dec -12.400.150.180.110.110.00---
RARE Dec ----------
TMDX Dec --n/m0.620.330.520.31---
TGTX Dec 0.000.000.000.750.060.291.210.631.100.38
GKOS Dec ----------
TARS Dec -----0.000.100.150.320.21
Peer median0.450.580.410.260.110.290.230.401.100.38

EPS (diluted), FY2016 to FY2025

Diluted earnings per share, on today's share count after splits.

−$17.48 $4.89 FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 IRTC: −$3.95, −$1.31, −$2.11, −$2.16, −$1.58, −$3.46, −$3.88, −$4.04, −$3.63, −$1.39 IRTC SUPN: $1.76, $1.08, $2.05, $2.10, $2.36, $0.98, $1.04, $0.02, $1.32, −$0.68 SUPN AXSM: −$1.42, −$1.27, −$1.15, −$2.01, −$2.77, −$3.47, −$4.60, −$5.27, −$5.99, −$3.68 AXSM INSP: −$16.90, −$14.88, −$1.50, −$1.40, −$2.19, −$1.54, −$1.60, −$0.72, $1.75, $4.89 INSP RARE: −$6.21, −$7.12, −$3.97, −$7.12, −$3.07, −$6.70, −$10.12, −$8.25, −$6.29, −$5.83 RARE TMDX: -, -, −$17.48, −$2.36, −$1.16, −$1.60, −$1.23, −$0.77, $1.01, $4.87 TMDX TGTX: −$1.60, −$1.91, −$2.30, −$1.96, −$2.42, −$2.63, −$1.65, $0.09, $0.15, $2.77 TGTX GKOS: $0.12, $0.00, −$0.37, $0.37, −$2.70, −$1.07, −$2.09, −$2.78, −$2.77, −$3.28 GKOS TARS: -, -, -, −$1.98, −$4.32, −$0.67, −$2.52, −$4.62, −$3.07, −$1.59 TARS RGEN: $0.34, $0.72, $0.37, $0.44, $1.11, $2.24, $3.24, $0.63, −$0.46, $0.86 RGEN
RGEN is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −$17.48 to $4.89. A gap is a year with no number. A ring marks where a line starts: TMDX, TARS have no earlier 10-K here.

Fiscal years are lined up as each company's 10-K names them; the month next to a ticker is when its year ends. Hover a number for the XBRL line items and the filing; click it to open the filing on sec.gov. "n/m" means not meaningful: equity below zero, or a base so close to zero that the ratio says nothing. The peer median leaves out RGEN and needs at least three peers with the number. P/E, P/S and P/FCF at each year end appear here once the site has daily prices. What the same companies write about AI, tariffs and more

Sources

Each company's 10-K, from SEC's XBRL company facts. Every number links to its filing in the Inline XBRL viewer.

Also

Financials: RGEN's own statements, year by year. Compare: the whole peer group on one page.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RGEN/export.csv") into a cell.

Next:Industry numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.